These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 3442244)

  • 1. Neurotensin reduces the affinity of D-2 dopamine receptors in rat striatal membranes.
    Von Euler G; Fuxe K
    Acta Physiol Scand; 1987 Dec; 131(4):625-6. PubMed ID: 3442244
    [No Abstract]   [Full Text] [Related]  

  • 2. Neurotensin modulates the binding characteristics of dopamine D2 receptors in rat striatal membranes also following treatment with toluene.
    von Euler G; Fuxe K; Benfenati F; Hansson T; Agnati LF; Gustafsson JA
    Acta Physiol Scand; 1989 Apr; 135(4):443-8. PubMed ID: 2525310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraventricular injection of neurotensin reduces the binding of dopamine D-2 receptors in the rat forebrain.
    von Euler G; Meister B; Hökfelt T; Fuxe K
    Acta Physiol Scand; 1989 Oct; 137(2):309-10. PubMed ID: 2618764
    [No Abstract]   [Full Text] [Related]  

  • 4. Interactions of a partial ergoline with dopamine receptors in vivo and in vitro.
    Fuxe K; Goldstein M; Agnati LF; Köhler C; Lew JY; Okada K
    Acta Physiol Scand; 1983 Feb; 117(2):303-5. PubMed ID: 6869037
    [No Abstract]   [Full Text] [Related]  

  • 5. Neurotensin decreases the affinity of dopamine D2 agonist binding by a G protein-independent mechanism.
    von Euler G; van der Ploeg I; Fredholm BB; Fuxe K
    J Neurochem; 1991 Jan; 56(1):178-83. PubMed ID: 1824779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholecystokinin peptides in vitro modulate the characteristics of the striatal 3H-N-propylnorapomorphine sites.
    Agnati LF; Celani MF; Fuxe K
    Acta Physiol Scand; 1983 May; 118(1):79-81. PubMed ID: 6312748
    [No Abstract]   [Full Text] [Related]  

  • 7. Neurotensin in vitro markedly reduces the affinity in subcortical limbic 3H-N-propylnorapomorphine binding sites.
    Agnati LF; Fuxe K; Benfenati F; Battistini N
    Acta Physiol Scand; 1983 Dec; 119(4):459-61. PubMed ID: 6320589
    [No Abstract]   [Full Text] [Related]  

  • 8. The effects of (-)N-(chloroethyl)-norapomorphine on [3H]-apomorphine binding to striatal dopamine receptors.
    Goosey MW; Doggett NS
    Biochem Pharmacol; 1982 Nov; 31(22):3693-4. PubMed ID: 7181954
    [No Abstract]   [Full Text] [Related]  

  • 9. Neuromedin N is a potent modulator of dopamine D2 receptor agonist binding in rat neostriatal membranes.
    Li XM; Finnman UB; von Euler G; Hedlund PB; Fuxe K
    Neurosci Lett; 1993 Jun; 155(2):121-4. PubMed ID: 8104321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and structural requirements of N-substituted norapomorphines for affinity and activity at dopamine D-1, D-2, and agonist receptor sites in rat brain.
    Gao YG; Ram VJ; Campbell A; Kula NS; Baldessarini RJ; Neumeyer JL
    J Med Chem; 1990 Jan; 33(1):39-44. PubMed ID: 2136919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurotensin reduces the affinity of dopamine D2 receptors in membranes from post mortem human caudate-putamen.
    von Euler G; Mailleux P; Vanderhaeghen JJ; Fuxe K
    Neurosci Lett; 1990 Feb; 109(3):325-30. PubMed ID: 2139501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and dopamine receptor affinity of (R)-(-)-2-fluoro-N-n-propylnorapomorphine: a highly potent and selective dopamine D2 agonist.
    Neumeyer JL; Gao YG; Kula NS; Baldessarini RJ
    J Med Chem; 1990 Dec; 33(12):3122-4. PubMed ID: 2147956
    [No Abstract]   [Full Text] [Related]  

  • 13. Ganglioside GM1 treatment prevents the effects of subacute exposure to toluene on N-[3H]propylnorapomorphine binding characteristics in rat striatal membranes.
    von Euler G; Fuxe K; Agnati LF; Hansson T; Gustafsson JA
    Neurosci Lett; 1987 Nov; 82(2):181-4. PubMed ID: 3696491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies of neurotensin-dopamine receptor interactions in striatal membranes of the male rat. The influence of 6-hydroxydopamine-induced dopamine receptor supersensitivity.
    Fuxe K; Agnati LF; Martire M; Neumeyer A; Benfenati F; Frey P
    Acta Physiol Scand; 1986 Jan; 126(1):147-9. PubMed ID: 3006432
    [No Abstract]   [Full Text] [Related]  

  • 15. Neurotensin facilitates dopamine release in vitro from rat striatal slices.
    de Quidt ME; Emson PC
    Brain Res; 1983 Sep; 274(2):376-80. PubMed ID: 6626967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacological comparison of 6,7-dihydroxy-2-dimethylaminotetralin (TL-99) and N-n-propyl-3-(3-hydroxyphenyl)piperidine with (3-PPP) selected dopamine agonists.
    Martin GE; Williams M; Haubrich DR
    J Pharmacol Exp Ther; 1982 Nov; 223(2):298-304. PubMed ID: 6813451
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of haloperidol and apomorphine treatment on dopamine receptors in pituitary and striatum.
    Friend WC; Brown GM; Jawahir G; Lee T; Seeman P
    Am J Psychiatry; 1978 Jul; 135(7):839-41. PubMed ID: 665797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurotensin effects on brain dopaminergic systems.
    Haubrich DR; Martin GE; Pflueger AB; Williams M
    Brain Res; 1982 Jan; 231(1):216-21. PubMed ID: 7198926
    [No Abstract]   [Full Text] [Related]  

  • 19. Neurotensin effect on dopamine release and calcium transport in rat striatum: interactions with diphenylalkylamine calcium antagonists.
    Battaini F; Govoni S; Di Giovine S; Trabucchi M
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Mar; 332(3):267-70. PubMed ID: 3713871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term adaptive changes in striatal dopamine function in response to chronic neuroleptic intake in rats.
    Jenner P; Kerwin R; Rupniak NM; Murugaiah K; Hall MD; Fleminger S; Marsden CD
    J Neural Transm Suppl; 1983; 18():205-12. PubMed ID: 6135741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.